N@N

Aegion Corp (NASDAQ:AEGN), Up By 14.34% ($2.27) After BUYINS.NET SqueezeTrigger Report Released on Monday, June 25th 2012 at a

^{Published on 2012-07-02 07:41:28 - WOPRAI}
 

July 2, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, released a report on Monday, June 25th 2012 at 05:16:00 PDT stating that Aegion Corp (NASDAQ:AEGN) was expected to be Up After it crossed above its SqueezeTrigger Price of 15.84 on Monday, June 25th 2012. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=aegn&id=287550

From August 2009 to June 2012, an aggregate amount of 8134517 shares of AEGN have been shorted for a total dollar value of $122017755. The AEGN SqueezeTrigger price of $15.84 is the volume weighted average price that all shorts are short in shares of AEGN. There is still approximately $71,497,917 of potential short covering in shares of AEGN.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

Aegion Corp (NASDAQ:AEGN) - Aerogen, Inc. (Aerogen), incorporated in November 1991, is a specialty pharmaceutical company that develops drug products focusing on respiratory therapy in the acute care setting. Based on its OnQ Aerosol Generator (OnQ) for aerosolizing liquids, it has developed and commercially introduced nebulizers that optimize aerosol production for use in both the home and hospital. The Company is also developing pulmonary drug delivery products in collaboration with partner companies for respiratory therapy and systemic drug input. Aerogen's lead therapeutic product, in a Phase II clinical trial, is an aerosolized antibiotic comprising a formulation of amikacin delivered via Aerogen's Pulmonary Drug Delivery System (PDDS") for the treatment of patients on ventilators with ventilator-associated pneumonia (VAP). This Phase II clinical trial was initiated on December 28, 2004, and involves the enrollment of 108 patients at approximately 31 study sites, with each patient to be studied for 28 consecutive days.

The PDDS consists of a software-driven controller, which is capable of sensing the performance of the ventilator and aerosolizing the drug during a predetermined portion of the ventilator cycle. It incorporates an OnQ with a particle size that has been customized for the individual therapeutic application. The Company does not intend to market the PDDS as a stand-alone device, as it intends to use it exclusively for delivery of drug products in the acute care setting. Aerogen's nebulizer products include Aeroneb Portable Nebulizer System, Aeroneb Go Nebulizer and Aeroneb Professional Nebulizer System.

Aeroneb Go Nebulizer

Aeroneb Go Nebulizer received the Conformite Europeenne (CE) mark in July 2003, and received 510(k) clearance from the United states Food and Drug Administration (FDA) in November 2003. This product replaces the Aeroneb Portable Nebulizer System in the home market. The Aeroneb Go is a nebulizer developed for patients worldwide that require respiratory therapy in and away from home. It allows patients to complete their treatments with minimal wasted medication and delivers a respirable aerosol.

In June 2003, the Company made initial commercial shipments of the product to Norway via its distributor Normed, as part of a test market. In September 2003, it entered into an agreement with Medical Industries America Inc. for marketing and manufacturing of the Aeroneb Go. First commercial shipments occurred in the United States in January 2004.

Aeroneb Professional Nebulizer System

Aeroneb Professional Nebulizer System was CE marked in Europe, and FDA clearance in the United States as a general-purpose nebulizer intended to aerosolize physician-prescribed solutions for inhalation. The product is designed to improve the efficiency of drug delivery and reduce personnel and drug costs associated with inpatient care, particularly for patients on ventilators. The Aeroneb Pro can be used not only on the ventilator but also in the hospital or in an ambulance and it can also be used with both adult and children's masks. The device is autoclaveable, so it is suitable for multi-patient use, and its low residual volume allows efficient drug delivery to the lungs.

The Aeroneb Pro System is small and lightweight, allowing it to be positioned close to the patient's airway and is designed to allow the addition of medication to the nebulizer without opening the ventilator tubing. The drug is aerosolized without the use of compressed air and therefore avoids the introduction of additional air and pressure into the ventilator circuit. The Company has developed a version of the Aeroneb Pro specifically for use in animal testing laboratories, marketed as the Aeroneb Lab.

Aerogen has entered into a worldwide, non-exclusive supply agreement with Datex-Ohmeda, Inc., a division of Instrumentarium, which was acquired by GE Healthcare in October 2003. Under the agreement, Aerogen is supplying GE Healthcare with a customized version of the Aeroneb Pro for integration into future products designed for critical care. G

The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net